Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients
•Tocilizumab (TCZ) is currently being tested in COVID‐19‐induced cytokine storm.•COVID-19 patients responding to TCZ have higher post-treatment levels of circulating miR-146a.•Low levels of miR-146a are associated with death in COVID-19 patients not responding to TCZ.•MicroRNAs can represent biomark...
Saved in:
| Published in | Mechanisms of ageing and development Vol. 193; p. 111413 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Ireland
Elsevier B.V
01.01.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0047-6374 1872-6216 1872-6216 |
| DOI | 10.1016/j.mad.2020.111413 |
Cover
Loading…
| Abstract | •Tocilizumab (TCZ) is currently being tested in COVID‐19‐induced cytokine storm.•COVID-19 patients responding to TCZ have higher post-treatment levels of circulating miR-146a.•Low levels of miR-146a are associated with death in COVID-19 patients not responding to TCZ.•MicroRNAs can represent biomarkers of response to anti-inflammatory interventions in COVID-19.
Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia.
In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR.
We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat. |
|---|---|
| AbstractList | Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat.Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat. Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat. •Tocilizumab (TCZ) is currently being tested in COVID‐19‐induced cytokine storm.•COVID-19 patients responding to TCZ have higher post-treatment levels of circulating miR-146a.•Low levels of miR-146a are associated with death in COVID-19 patients not responding to TCZ.•MicroRNAs can represent biomarkers of response to anti-inflammatory interventions in COVID-19. Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat. Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat. |
| ArticleNumber | 111413 |
| Author | Procopio, Antonio Domenico Sabbatinelli, Jacopo Olivieri, Fabiola Ferracin, Manuela Svegliati Baroni, Silvia Bonafè, Massimiliano Pavani, Marianna Giuliani, Angelica Ferrarini, Alessia Latini, Silvia Laprovitera, Noemi Gabrielli, Armando Pomponio, Giovanni Matacchione, Giulia Moretti, Marco |
| Author_xml | – sequence: 1 givenname: Jacopo orcidid: 0000-0001-9947-6778 surname: Sabbatinelli fullname: Sabbatinelli, Jacopo organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 2 givenname: Angelica surname: Giuliani fullname: Giuliani, Angelica organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 3 givenname: Giulia surname: Matacchione fullname: Matacchione, Giulia organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 4 givenname: Silvia surname: Latini fullname: Latini, Silvia organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 5 givenname: Noemi orcidid: 0000-0002-2737-4665 surname: Laprovitera fullname: Laprovitera, Noemi organization: Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy – sequence: 6 givenname: Giovanni surname: Pomponio fullname: Pomponio, Giovanni organization: Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy – sequence: 7 givenname: Alessia surname: Ferrarini fullname: Ferrarini, Alessia organization: Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy – sequence: 8 givenname: Silvia surname: Svegliati Baroni fullname: Svegliati Baroni, Silvia organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 9 givenname: Marianna surname: Pavani fullname: Pavani, Marianna organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 10 givenname: Marco surname: Moretti fullname: Moretti, Marco organization: Laboratory Medicine, Ospedali Riuniti, Ancona, Italy – sequence: 11 givenname: Armando surname: Gabrielli fullname: Gabrielli, Armando organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 12 givenname: Antonio Domenico surname: Procopio fullname: Procopio, Antonio Domenico organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy – sequence: 13 givenname: Manuela orcidid: 0000-0002-1595-6887 surname: Ferracin fullname: Ferracin, Manuela email: manuela.ferracin@unibo.it organization: Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy – sequence: 14 givenname: Massimiliano orcidid: 0000-0002-5218-6551 surname: Bonafè fullname: Bonafè, Massimiliano email: massimiliano.bonafe@unibo.it organization: Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy – sequence: 15 givenname: Fabiola orcidid: 0000-0002-9606-1144 surname: Olivieri fullname: Olivieri, Fabiola email: f.olivieri@univpm.it organization: Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33307107$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV9rFDEUxYNU7Lb6AXyRPPoya_7NzA6CIFurhUJB1NdwN7mzmzUzWZPMFv0Efuxm2VbUh0IghNzfOck5Z-RkDCMS8pKzOWe8ebOdD2Dngoly5lxx-YTM-KIVVSN4c0JmjKm2amSrTslZSlvGGFeieUZOpZSs5aydkd8XaCJCQksTxmmgHvfoEw09zRukbuw9DAOs3bimA8TvGOngPldcNUAhIoWUgnGQC3_r8oYa70ZnwNPy1Cpi2oUxIc2hLOO8-zUNsCqqdHnz7eqi4h3dQXY45vScPO3BJ3xxv5-Tr5cfviw_Vdc3H6-W768rIxc8V1w0K6EYiN50XK4aWwM2AoSyvTLG1NDbztbIeguKiYW0omO1kGD6GkUHRp6Td0fd3bQa0JriHcHrXXTlez91AKf_vRndRq_DXretEKpTReD1vUAMPyZMWQ8uGfQeRgxT0kK1jMlaiK6Mvvrb64_JQ_xloD0OmBhSithr43IJJBysndec6UPReqtL0fpQtD4WXUj-H_kg_hjz9siUgnHvMOpkSvYGrYtosrbBPULfAeX4wkU |
| CitedBy_id | crossref_primary_10_1016_j_prmcm_2022_100049 crossref_primary_10_1016_j_jff_2024_106530 crossref_primary_10_1089_can_2023_0040 crossref_primary_10_1007_s11357_022_00536_0 crossref_primary_10_3390_bioengineering9080352 crossref_primary_10_1016_j_msard_2021_103126 crossref_primary_10_1155_2022_1645366 crossref_primary_10_1186_s13054_022_03948_8 crossref_primary_10_3390_ph15111330 crossref_primary_10_1038_s41392_023_01669_0 crossref_primary_10_3389_fimmu_2021_739592 crossref_primary_10_3389_fimmu_2022_825103 crossref_primary_10_3389_fmed_2024_1430974 crossref_primary_10_1016_j_isci_2021_103672 crossref_primary_10_1016_j_gene_2024_148370 crossref_primary_10_3390_ph15070783 crossref_primary_10_3390_ijms23169239 crossref_primary_10_1124_jpet_122_001210 crossref_primary_10_3390_ncrna7030054 crossref_primary_10_2174_26669587_v2_e221026_2022_23 crossref_primary_10_3390_ijms241713037 crossref_primary_10_3892_ijmm_2022_5210 crossref_primary_10_7717_peerj_18856 crossref_primary_10_1016_j_intimp_2021_108071 crossref_primary_10_1007_s11033_022_07338_9 crossref_primary_10_3390_biom13121681 crossref_primary_10_3390_ijms241310992 crossref_primary_10_3390_jcm10235712 crossref_primary_10_1016_j_pupt_2023_102196 crossref_primary_10_3390_life12020288 crossref_primary_10_1007_s11010_022_04356_w crossref_primary_10_3390_ijms24043574 crossref_primary_10_1016_j_mad_2022_111636 crossref_primary_10_1002_clc_24274 crossref_primary_10_1016_j_arr_2021_101374 crossref_primary_10_1097_MD_0000000000038378 crossref_primary_10_3390_ijms232012292 crossref_primary_10_1089_dna_2021_1101 crossref_primary_10_1016_j_intimp_2022_108536 crossref_primary_10_1007_s10639_022_11484_9 crossref_primary_10_1080_22221751_2022_2038021 crossref_primary_10_1186_s10020_022_00527_z crossref_primary_10_2217_bmm_2021_0348 crossref_primary_10_3389_fnmol_2023_1123955 crossref_primary_10_1016_j_virusres_2021_198631 crossref_primary_10_3390_v15051177 crossref_primary_10_1002_rmv_2562 crossref_primary_10_3390_diagnostics13010133 crossref_primary_10_1016_j_jped_2023_06_004 crossref_primary_10_1016_j_genrep_2022_101641 crossref_primary_10_3390_ijms22168663 crossref_primary_10_3390_ijms241612767 crossref_primary_10_2147_DDDT_S308863 crossref_primary_10_3390_medicina57060575 crossref_primary_10_1016_j_biopha_2024_116984 crossref_primary_10_1039_D2SD00140C crossref_primary_10_3892_etm_2024_12427 crossref_primary_10_1134_S0026893322010034 crossref_primary_10_1007_s12016_021_08909_7 crossref_primary_10_3390_cells12192421 crossref_primary_10_3390_jpm12030386 crossref_primary_10_3390_v14010041 crossref_primary_10_1002_rmv_2449 crossref_primary_10_1002_rmv_2526 crossref_primary_10_2139_ssrn_3940630 crossref_primary_10_3390_diagnostics13152508 crossref_primary_10_1111_all_15480 crossref_primary_10_1016_j_ijbiomac_2022_09_105 crossref_primary_10_1038_s41598_023_40754_w crossref_primary_10_3389_fcimb_2022_998748 crossref_primary_10_1016_j_intimp_2022_109040 crossref_primary_10_1002_med_22073 crossref_primary_10_33393_jcb_2022_2356 crossref_primary_10_7717_peerj_12370 crossref_primary_10_2217_epi_2023_0179 crossref_primary_10_3389_fnagi_2022_1020092 crossref_primary_10_3390_life12040575 crossref_primary_10_1016_j_jmccpl_2022_100013 crossref_primary_10_1016_j_meegid_2024_105613 crossref_primary_10_1016_j_mad_2022_111667 crossref_primary_10_3389_fphar_2021_765553 crossref_primary_10_3390_biology12101334 crossref_primary_10_3390_ijms22105263 crossref_primary_10_2174_1389200223666220321102824 crossref_primary_10_1016_j_jiph_2022_06_012 crossref_primary_10_1038_s41598_023_49601_4 crossref_primary_10_1016_j_trsl_2021_05_004 crossref_primary_10_3390_ijms24032380 crossref_primary_10_1016_j_gene_2021_146069 crossref_primary_10_3390_ijms231810536 |
| Cites_doi | 10.1136/annrheumdis-2020-218479 10.1182/blood.2019002045 10.1073/pnas.2005615117 10.7150/ijbs.47652 10.1016/j.mad.2012.09.004 10.3389/fgene.2013.00121 10.3389/fimmu.2015.00019 10.1016/j.mad.2019.03.001 10.1002/jmv.25801 10.3389/fimmu.2016.00604 10.1002/jcph.1693 10.1371/journal.pone.0052782 10.1084/jem.20101823 10.1016/S1470-2045(12)70073-6 10.1016/S0140-6736(20)30937-5 10.1007/s11357-012-9440-8 10.1038/s41598-019-39873-0 10.3389/fnins.2020.00311 10.1007/s11357-011-9348-8 10.1182/blood.2019003105 10.1007/s40259-020-00430-1 10.1038/s41591-020-0944-y 10.3389/fimmu.2019.00085 10.1155/2018/7671850 10.1096/fj.201701536R 10.18632/oncotarget.3859 10.1002/j.1460-2075.1990.tb08316.x 10.1038/srep38339 10.1016/S0140-6736(20)31042-4 10.3389/fimmu.2020.00566 10.1007/s00134-020-05991-x 10.1016/S0140-6736(20)30566-3 10.1007/s00330-020-06817-6 10.1016/j.jaut.2020.102452 10.1016/j.cytogfr.2020.04.005 10.1080/20013078.2020.1725285 10.1016/S0140-6736(20)30627-9 10.1007/s10753-015-0153-x |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. – notice: 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.mad.2020.111413 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology Zoology |
| EISSN | 1872-6216 |
| EndPage | 111413 |
| ExternalDocumentID | PMC7722494 33307107 10_1016_j_mad_2020_111413 S0047637420302098 |
| Genre | Multicenter Study Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29M 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXLA AAXUO AAYJJ ABCQJ ABFNM ABFRF ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGWIK AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HMQ HVGLF HZ~ IHE J1W KOM LX3 M2V M41 MO0 MOBAO MS~ MVM N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SBG SCC SDF SDG SDP SES SEW SNS SPCBC SSN SSU SSZ T5K WUQ X7M YYP ZGI ZXP ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EIF NPM 7X8 5PM EFKBS |
| ID | FETCH-LOGICAL-c381t-126b240a2fc913b6d5ae62a24df4ccc5afd9d5e0fda40283d290523acf5e29ac3 |
| IEDL.DBID | .~1 |
| ISSN | 0047-6374 1872-6216 |
| IngestDate | Thu Aug 21 18:33:34 EDT 2025 Fri Jul 11 02:17:40 EDT 2025 Thu Apr 03 07:03:14 EDT 2025 Tue Jul 01 04:17:45 EDT 2025 Thu Apr 24 23:07:26 EDT 2025 Fri Feb 23 02:44:40 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 microRNA Inflammaging Tocilizumab interleukin-6 |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c381t-126b240a2fc913b6d5ae62a24df4ccc5afd9d5e0fda40283d290523acf5e29ac3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-5218-6551 0000-0001-9947-6778 0000-0002-9606-1144 0000-0002-2737-4665 0000-0002-1595-6887 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7722494 |
| PMID | 33307107 |
| PQID | 2470035229 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7722494 proquest_miscellaneous_2470035229 pubmed_primary_33307107 crossref_citationtrail_10_1016_j_mad_2020_111413 crossref_primary_10_1016_j_mad_2020_111413 elsevier_sciencedirect_doi_10_1016_j_mad_2020_111413 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland |
| PublicationTitle | Mechanisms of ageing and development |
| PublicationTitleAlternate | Mech Ageing Dev |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Xu, Han, Li, Sun, Wang, Fu, Zhou, Zheng, Yang, Li, Zhang, Pan, Wei (bib0200) 2020; 117 Wilk, Rustagi, Zhao, Roque, Martinez-Colon, McKechnie, Ivison, Ranganath, Vergara, Hollis, Simpson, Grant, Subramanian, Rogers, Blish (bib0190) 2020; 26 Roos, Enlund, Funcke, Tews, Holzmann, Debatin, Wabitsch, Fischer-Posovszky (bib0145) 2016; 6 Luo, Liu, Qiu, Liu, Liu, Li (bib0090) 2020; 92 Zhong, Simard, Huot (bib0210) 2018; 32 Grants, Wegrzyn, Hui, O’Neill, Shadbolt, Knapp, Parker, Deng, Gopal, Docking, Fuller, Li, Boldin, Eaves, Hirst, Karsan (bib0040) 2020; 135 Crisafulli, Isgro, La Corte, Atzeni, Trifiro (bib0025) 2020; 34 Ong, Woldhuis, Boudewijn, van den Berg, Kluiver, Kok, Terpstra, Guryev, de Vries, Vermeulen, Timens, van den Berge, Brandsma (bib0130) 2019; 9 Feng, Wang, Ye, Guan, Tan, Cheng, Wei, Wu, Wu, Zhou (bib0030) 2012; 7 Varga, Flammer, Steiger, Haberecker, Andermatt, Zinkernagel, Mehra, Schuepbach, Ruschitzka, Moch (bib0185) 2020; 395 Luo, Zheng (bib0095) 2016; 7 Ramiro, Mostard, Magro-Checa, van Dongen, Dormans, Buijs, Gronenschild, de Kruif, van Haren, van Kraaij, Leers, Peeters, Wong, Landewe (bib0135) 2020; 79 Libermann, Baltimore (bib0075) 1990; 10 Mensà, Giuliani, Matacchione, Gurău, Bonfigli, Romagnoli, De Luca, Sabbatinelli, Olivieri (bib0100) 2019; 180 Olivieri, Spazzafumo, Santini, Lazzarini, Albertini, Rippo, Galeazzi, Abbatecola, Marcheselli, Monti, Ostan, Cevenini, Antonicelli, Franceschi, Procopio (bib0115) 2012; 133 Khiali, Khani, Entezari-Maleki (bib0055) 2020; 60 Li, Ji, Li, Sun, Liu, Liu, Tian, Zhou, Shang (bib0065) 2015; 38 Boldin, Taganov, Rao, Yang, Zhao, Kalwani, Garcia-Flores, Luong, Devrekanli, Xu, Sun, Tay, Linsley, Baltimore (bib0015) 2011; 208 Istituto Superiore di Sanità (bib0050) 2020 Sheedy (bib0160) 2015; 6 Xiang, Liu, Shi, Chen, Li, Yan, Bi, Hu, Zhu, Yu, Yang (bib0195) 2020; 16 Bonafè, Prattichizzo, Giuliani, Storci, Sabbatinelli, Olivieri (bib0020) 2020; 53 Spazzafumo, Olivieri, Abbatecola, Castellani, Monti, Lisa, Galeazzi, Sirolla, Testa, Ostan, Scurti, Caruso, Vasto, Vescovini, Ogliari, Mari, Lattanzio, Franceschi (bib0165) 2013; 35 Zhang, Wang, Fan, Tu, Yang, Ha, Liu, Kalbfleisch, Williams, Li (bib0205) 2020; 11 Mensà, Guescini, Giuliani, Bacalini, Ramini, Corleone, Ferracin, Fulgenzi, Graciotti, Prattichizzo, Sorci, Battistelli, Monsurrò, Bonfigli, Cardelli, Recchioni, Marcheselli, Latini, Maggio, Fanelli, Amatori, Storci, Ceriello, Stocchi, De Luca, Magnani, Rippo, Procopio, Sala, Budimir, Bassi, Negrini, Garagnani, Franceschi, Sabbatinelli, Bonafè, Olivieri (bib0105) 2020; 9 Olivieri, Lazzarini, Recchioni, Marcheselli, Rippo, Di Nuzzo, Albertini, Graciotti, Babini, Mariotti, Spada, Abbatecola, Antonicelli, Franceschi, Procopio (bib0120) 2013; 35 Ruan, Yang, Wang, Jiang, Song (bib0150) 2020; 46 Ferracin, Lupini, Salamon, Saccenti, Zanzi, Rocchi, Da Ros, Zagatti, Musa, Bassi, Mangolini, Cavallesco, Frassoldati, Volpato, Carcoforo, Hollingsworth, Negrini (bib0035) 2015; 6 Akira, Isshiki, Sugita, Tanabe, Kinoshita, Nishio, Nakajima, Hirano, Kishimoto (bib0005) 1990; 9 Olivieri, Rippo, Procopio, Fazioli (bib0125) 2013; 4 Su, Wang, Mann, Adamus, Wang, Moreira, Zhang, Ouyang, He, Zhang, Swiderski, Forman, Baltimore, Li, Marcucci, Boldin, Kortylewski (bib0180) 2020; 135 Liu, Zhang, Gao, Wang, Tao, Gao, Zhou, Chen, Li, Hang (bib0085) 2020; 14 Kong, Ferland-McCollough, Jackson, Bushell (bib0060) 2012; 13 Rusanova, Diaz-Casado, Fernandez-Ortiz, Aranda-Martinez, Guerra-Librero, Garcia-Garcia, Escames, Manas, Acuna-Castroviejo (bib0155) 2018; 2018 Liu, Li, Zhou, Guan, Xiang (bib0080) 2020; 111 Remuzzi, Remuzzi (bib0140) 2020; 395 Li, Fang, Li, Pan, Qin, Zhong, Liu, Huang, Liao, Li (bib0070) 2020; 30 Zhou, Yu, Du, Fan, Liu, Liu, Xiang, Wang, Song, Gu, Guan, Wei, Li, Wu, Xu, Tu, Zhang, Chen, Cao (bib0220) 2020; 395 Benz, Roy, Trautwein, Roderburg, Luedde (bib0010) 2016 Mussbacher, Salzmann, Brostjan, Hoesel, Schoergenhofer, Datler, Hohensinner, Basilio, Petzelbauer, Assinger, Schmid (bib0110) 2019; 10 Zhou, Zhao, Wang, Qi, Wang, Yang, Sun, Mu (bib0215) 2019; 18 Hung, Lung, Tso, Liu, Chung, Chu, Ng, Lo, Chan, Tam, Shum, Chan, Wu, Sin, Leung, Law, Lung, Sin, Yeung, Yip, Zhang, Fung, Yan, Leung, Ip, Chu, Chan, Ng, Lee, Fung, Yeung, Wu, Chan, Yan, Chan, Chan, Lie, Tsang, Cheng, Que, Lau, Chan, To, Yuen (bib0045) 2020; 395 Sriram, Insel (bib0170) 2020 Storci, Bonifazi, Garagnani, Olivieri, Bonafe (bib0175) 2020 Liu (10.1016/j.mad.2020.111413_bib0085) 2020; 14 Remuzzi (10.1016/j.mad.2020.111413_bib0140) 2020; 395 Zhou (10.1016/j.mad.2020.111413_bib0215) 2019; 18 Ruan (10.1016/j.mad.2020.111413_bib0150) 2020; 46 Mussbacher (10.1016/j.mad.2020.111413_bib0110) 2019; 10 Roos (10.1016/j.mad.2020.111413_bib0145) 2016; 6 Zhang (10.1016/j.mad.2020.111413_bib0205) 2020; 11 Akira (10.1016/j.mad.2020.111413_bib0005) 1990; 9 Istituto Superiore di Sanità (10.1016/j.mad.2020.111413_bib0050) 2020 Libermann (10.1016/j.mad.2020.111413_bib0075) 1990; 10 Boldin (10.1016/j.mad.2020.111413_bib0015) 2011; 208 Li (10.1016/j.mad.2020.111413_bib0070) 2020; 30 Olivieri (10.1016/j.mad.2020.111413_bib0115) 2012; 133 Sheedy (10.1016/j.mad.2020.111413_bib0160) 2015; 6 Li (10.1016/j.mad.2020.111413_bib0065) 2015; 38 Ong (10.1016/j.mad.2020.111413_bib0130) 2019; 9 Benz (10.1016/j.mad.2020.111413_bib0010) 2016 Luo (10.1016/j.mad.2020.111413_bib0090) 2020; 92 Olivieri (10.1016/j.mad.2020.111413_bib0120) 2013; 35 Sriram (10.1016/j.mad.2020.111413_bib0170) 2020 Feng (10.1016/j.mad.2020.111413_bib0030) 2012; 7 Ferracin (10.1016/j.mad.2020.111413_bib0035) 2015; 6 Liu (10.1016/j.mad.2020.111413_bib0080) 2020; 111 Rusanova (10.1016/j.mad.2020.111413_bib0155) 2018; 2018 Luo (10.1016/j.mad.2020.111413_bib0095) 2016; 7 Zhong (10.1016/j.mad.2020.111413_bib0210) 2018; 32 Xiang (10.1016/j.mad.2020.111413_bib0195) 2020; 16 Khiali (10.1016/j.mad.2020.111413_bib0055) 2020; 60 Crisafulli (10.1016/j.mad.2020.111413_bib0025) 2020; 34 Olivieri (10.1016/j.mad.2020.111413_bib0125) 2013; 4 Spazzafumo (10.1016/j.mad.2020.111413_bib0165) 2013; 35 Xu (10.1016/j.mad.2020.111413_bib0200) 2020; 117 Storci (10.1016/j.mad.2020.111413_bib0175) 2020 Hung (10.1016/j.mad.2020.111413_bib0045) 2020; 395 Mensà (10.1016/j.mad.2020.111413_bib0105) 2020; 9 Su (10.1016/j.mad.2020.111413_bib0180) 2020; 135 Mensà (10.1016/j.mad.2020.111413_bib0100) 2019; 180 Wilk (10.1016/j.mad.2020.111413_bib0190) 2020; 26 Ramiro (10.1016/j.mad.2020.111413_bib0135) 2020; 79 Zhou (10.1016/j.mad.2020.111413_bib0220) 2020; 395 Grants (10.1016/j.mad.2020.111413_bib0040) 2020; 135 Kong (10.1016/j.mad.2020.111413_bib0060) 2012; 13 Varga (10.1016/j.mad.2020.111413_bib0185) 2020; 395 Bonafè (10.1016/j.mad.2020.111413_bib0020) 2020; 53 |
| References_xml | – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: bib0220 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet – volume: 34 start-page: 415 year: 2020 end-page: 422 ident: bib0025 article-title: Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks publication-title: BioDrugs. – volume: 53 start-page: 33 year: 2020 end-page: 37 ident: bib0020 article-title: Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes publication-title: Cytokine Growth Factor Rev. – year: 2020 ident: bib0170 article-title: Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets publication-title: Physiol. Rev. – volume: 7 start-page: e52782 year: 2012 ident: bib0030 article-title: Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha publication-title: PLoS One – volume: 46 start-page: 846 year: 2020 end-page: 848 ident: bib0150 article-title: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China publication-title: Intensive Care Med. – volume: 7 start-page: 604 year: 2016 ident: bib0095 article-title: Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms publication-title: Front. Immunol. – volume: 16 start-page: 2382 year: 2020 end-page: 2391 ident: bib0195 article-title: Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels publication-title: Int. J. Biol. Sci. – volume: 30 start-page: 4407 year: 2020 end-page: 4416 ident: bib0070 article-title: CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) publication-title: Eur. Radiol. – volume: 11 start-page: 566 year: 2020 ident: bib0205 article-title: Endothelial HSPA12B exerts protection against sepsis-induced severe cardiomyopathy via suppression of adhesion molecule expression by miR-126 publication-title: Front. Immunol. – volume: 10 start-page: 85 year: 2019 ident: bib0110 article-title: Cell type-specific roles of NF-kappaB linking inflammation and thrombosis publication-title: Front. Immunol. – volume: 395 start-page: 1695 year: 2020 end-page: 1704 ident: bib0045 article-title: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial publication-title: Lancet – volume: 111 year: 2020 ident: bib0080 article-title: Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? publication-title: J. Autoimmun. – volume: 6 start-page: 38339 year: 2016 ident: bib0145 article-title: miR-146a-mediated suppression of the inflammatory response in human adipocytes publication-title: Sci. Rep. – volume: 13 start-page: e249 year: 2012 end-page: 258 ident: bib0060 article-title: microRNAs in cancer management publication-title: Lancet Oncol. – volume: 133 start-page: 675 year: 2012 end-page: 685 ident: bib0115 article-title: Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging publication-title: Mech. Ageing Dev. – volume: 395 start-page: 1225 year: 2020 end-page: 1228 ident: bib0140 article-title: COVID-19 and Italy: what next? publication-title: Lancet – volume: 2018 year: 2018 ident: bib0155 article-title: Analysis of plasma MicroRNAs as predictors and biomarkers of aging and frailty in humans publication-title: Oxid. Med. Cell. Longev. – volume: 208 start-page: 1189 year: 2011 end-page: 1201 ident: bib0015 article-title: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice publication-title: J. Exp. Med. – year: 2020 ident: bib0050 article-title: Characteristics of COVID-19 Patients Dying in Italy – volume: 92 start-page: 814 year: 2020 end-page: 818 ident: bib0090 article-title: Tocilizumab treatment in COVID-19: a single center experience publication-title: J. Med. Virol. – volume: 117 start-page: 10970 year: 2020 end-page: 10975 ident: bib0200 article-title: Effective treatment of severe COVID-19 patients with tocilizumab publication-title: Proc Natl Acad Sci U S A – volume: 35 start-page: 1157 year: 2013 end-page: 1172 ident: bib0120 article-title: MiR-146a as marker of senescence-Associated pro-inflammatory status in cells involved in vascular remodelling publication-title: Age – volume: 4 start-page: 121 year: 2013 ident: bib0125 article-title: Circulating inflamma-miRs in aging and age-related diseases publication-title: Front. Genet. – volume: 9 start-page: 1897 year: 1990 end-page: 1906 ident: bib0005 article-title: A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family publication-title: EMBO J. – volume: 26 start-page: 1070 year: 2020 end-page: 1076 ident: bib0190 article-title: A single-cell atlas of the peripheral immune response in patients with severe COVID-19 publication-title: Nat. Med. – volume: 35 start-page: 419 year: 2013 end-page: 429 ident: bib0165 article-title: Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes publication-title: Age Dordr. (Dordr) – volume: 14 start-page: 311 year: 2020 ident: bib0085 article-title: MiR-146a ameliorates hemoglobin-induced microglial inflammatory response via TLR4/IRAK1/TRAF6 associated pathways publication-title: Front. Neurosci. – volume: 9 start-page: 3765 year: 2019 ident: bib0130 article-title: Age-related gene and miRNA expression changes in airways of healthy individuals publication-title: Sci. Rep. – start-page: 17 year: 2016 ident: bib0010 article-title: Circulating MicroRNAs as biomarkers for Sepsis publication-title: Int. J. Mol. Sci. – volume: 6 start-page: 14545 year: 2015 end-page: 14555 ident: bib0035 article-title: Absolute quantification of cell-free microRNAs in cancer patients publication-title: Oncotarget – volume: 6 start-page: 19 year: 2015 ident: bib0160 article-title: Turning 21: induction of miR-21 as a key switch in the inflammatory response publication-title: Front. Immunol. – volume: 135 start-page: 167 year: 2020 end-page: 180 ident: bib0180 article-title: Myeloid cell-targeted miR-146a mimic inhibits NF-kappaB-driven inflammation and leukemia progression in vivo publication-title: Blood – volume: 18 start-page: 3078 year: 2019 end-page: 3084 ident: bib0215 article-title: MicroRNA-146a inhibits NF-kappaB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells publication-title: Exp. Ther. Med. – volume: 60 start-page: 1131 year: 2020 end-page: 1146 ident: bib0055 article-title: A comprehensive review on tocilizumab in COVID-19 acute respiratory distress syndrome publication-title: J. Clin. Pharmacol. – volume: 38 start-page: 1761 year: 2015 end-page: 1768 ident: bib0065 article-title: miR-146a-5p antagonized AGEs- and P.g-LPS-Induced ABCA1 and ABCG1 dysregulation in macrophages via IRAK-1 downregulation publication-title: Inflammation – volume: 180 start-page: 1 year: 2019 end-page: 10 ident: bib0100 article-title: Circulating miR-146a in healthy aging and type 2 diabetes: age- and gender-specific trajectories publication-title: Mech. Ageing Dev. – volume: 395 start-page: 1417 year: 2020 end-page: 1418 ident: bib0185 article-title: Endothelial cell infection and endotheliitis in COVID-19 publication-title: Lancet – volume: 79 start-page: 1143 year: 2020 end-page: 1151 ident: bib0135 article-title: Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study publication-title: Ann. Rheum. Dis. – volume: 32 start-page: 4070 year: 2018 end-page: 4084 ident: bib0210 article-title: Endothelial microRNAs regulating the NF-kappaB pathway and cell adhesion molecules during inflammation publication-title: FASEB J. – volume: 135 start-page: 2235 year: 2020 end-page: 2251 ident: bib0040 article-title: Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice publication-title: Blood – year: 2020 ident: bib0175 article-title: How studies on inflamm-aging may help to understand and combat COVID-19 pandemic publication-title: Preprints – volume: 10 start-page: 2327 year: 1990 end-page: 2334 ident: bib0075 article-title: Activation of interleukin-6 gene expression through the NF-kappa B transcription factor publication-title: Mol. Cell. Biol. – volume: 9 year: 2020 ident: bib0105 article-title: Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells publication-title: J. Extracell. Vesicles – volume: 79 start-page: 1143 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0135 article-title: Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218479 – volume: 135 start-page: 167 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0180 article-title: Myeloid cell-targeted miR-146a mimic inhibits NF-kappaB-driven inflammation and leukemia progression in vivo publication-title: Blood doi: 10.1182/blood.2019002045 – volume: 117 start-page: 10970 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0200 article-title: Effective treatment of severe COVID-19 patients with tocilizumab publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.2005615117 – year: 2020 ident: 10.1016/j.mad.2020.111413_bib0050 – volume: 16 start-page: 2382 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0195 article-title: Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.47652 – volume: 133 start-page: 675 year: 2012 ident: 10.1016/j.mad.2020.111413_bib0115 article-title: Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging publication-title: Mech. Ageing Dev. doi: 10.1016/j.mad.2012.09.004 – volume: 4 start-page: 121 year: 2013 ident: 10.1016/j.mad.2020.111413_bib0125 article-title: Circulating inflamma-miRs in aging and age-related diseases publication-title: Front. Genet. doi: 10.3389/fgene.2013.00121 – volume: 6 start-page: 19 year: 2015 ident: 10.1016/j.mad.2020.111413_bib0160 article-title: Turning 21: induction of miR-21 as a key switch in the inflammatory response publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00019 – volume: 180 start-page: 1 year: 2019 ident: 10.1016/j.mad.2020.111413_bib0100 article-title: Circulating miR-146a in healthy aging and type 2 diabetes: age- and gender-specific trajectories publication-title: Mech. Ageing Dev. doi: 10.1016/j.mad.2019.03.001 – volume: 92 start-page: 814 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0090 article-title: Tocilizumab treatment in COVID-19: a single center experience publication-title: J. Med. Virol. doi: 10.1002/jmv.25801 – volume: 7 start-page: 604 year: 2016 ident: 10.1016/j.mad.2020.111413_bib0095 article-title: Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms publication-title: Front. Immunol. doi: 10.3389/fimmu.2016.00604 – volume: 60 start-page: 1131 issue: 9 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0055 article-title: A comprehensive review on tocilizumab in COVID-19 acute respiratory distress syndrome publication-title: J. Clin. Pharmacol. doi: 10.1002/jcph.1693 – volume: 7 start-page: e52782 year: 2012 ident: 10.1016/j.mad.2020.111413_bib0030 article-title: Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha publication-title: PLoS One doi: 10.1371/journal.pone.0052782 – volume: 208 start-page: 1189 year: 2011 ident: 10.1016/j.mad.2020.111413_bib0015 article-title: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice publication-title: J. Exp. Med. doi: 10.1084/jem.20101823 – volume: 13 start-page: e249 year: 2012 ident: 10.1016/j.mad.2020.111413_bib0060 article-title: microRNAs in cancer management publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70073-6 – volume: 395 start-page: 1417 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0185 article-title: Endothelial cell infection and endotheliitis in COVID-19 publication-title: Lancet doi: 10.1016/S0140-6736(20)30937-5 – volume: 18 start-page: 3078 year: 2019 ident: 10.1016/j.mad.2020.111413_bib0215 article-title: MicroRNA-146a inhibits NF-kappaB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells publication-title: Exp. Ther. Med. – volume: 35 start-page: 1157 year: 2013 ident: 10.1016/j.mad.2020.111413_bib0120 article-title: MiR-146a as marker of senescence-Associated pro-inflammatory status in cells involved in vascular remodelling publication-title: Age doi: 10.1007/s11357-012-9440-8 – volume: 9 start-page: 3765 year: 2019 ident: 10.1016/j.mad.2020.111413_bib0130 article-title: Age-related gene and miRNA expression changes in airways of healthy individuals publication-title: Sci. Rep. doi: 10.1038/s41598-019-39873-0 – volume: 14 start-page: 311 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0085 article-title: MiR-146a ameliorates hemoglobin-induced microglial inflammatory response via TLR4/IRAK1/TRAF6 associated pathways publication-title: Front. Neurosci. doi: 10.3389/fnins.2020.00311 – volume: 35 start-page: 419 year: 2013 ident: 10.1016/j.mad.2020.111413_bib0165 article-title: Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes publication-title: Age Dordr. (Dordr) doi: 10.1007/s11357-011-9348-8 – start-page: 17 year: 2016 ident: 10.1016/j.mad.2020.111413_bib0010 article-title: Circulating MicroRNAs as biomarkers for Sepsis publication-title: Int. J. Mol. Sci. – volume: 135 start-page: 2235 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0040 article-title: Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice publication-title: Blood doi: 10.1182/blood.2019003105 – year: 2020 ident: 10.1016/j.mad.2020.111413_bib0170 article-title: Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets publication-title: Physiol. Rev. – volume: 34 start-page: 415 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0025 article-title: Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks publication-title: BioDrugs. doi: 10.1007/s40259-020-00430-1 – volume: 26 start-page: 1070 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0190 article-title: A single-cell atlas of the peripheral immune response in patients with severe COVID-19 publication-title: Nat. Med. doi: 10.1038/s41591-020-0944-y – volume: 10 start-page: 85 year: 2019 ident: 10.1016/j.mad.2020.111413_bib0110 article-title: Cell type-specific roles of NF-kappaB linking inflammation and thrombosis publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00085 – volume: 2018 year: 2018 ident: 10.1016/j.mad.2020.111413_bib0155 article-title: Analysis of plasma MicroRNAs as predictors and biomarkers of aging and frailty in humans publication-title: Oxid. Med. Cell. Longev. doi: 10.1155/2018/7671850 – volume: 32 start-page: 4070 year: 2018 ident: 10.1016/j.mad.2020.111413_bib0210 article-title: Endothelial microRNAs regulating the NF-kappaB pathway and cell adhesion molecules during inflammation publication-title: FASEB J. doi: 10.1096/fj.201701536R – year: 2020 ident: 10.1016/j.mad.2020.111413_bib0175 article-title: How studies on inflamm-aging may help to understand and combat COVID-19 pandemic publication-title: Preprints – volume: 6 start-page: 14545 year: 2015 ident: 10.1016/j.mad.2020.111413_bib0035 article-title: Absolute quantification of cell-free microRNAs in cancer patients publication-title: Oncotarget doi: 10.18632/oncotarget.3859 – volume: 9 start-page: 1897 year: 1990 ident: 10.1016/j.mad.2020.111413_bib0005 article-title: A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family publication-title: EMBO J. doi: 10.1002/j.1460-2075.1990.tb08316.x – volume: 6 start-page: 38339 year: 2016 ident: 10.1016/j.mad.2020.111413_bib0145 article-title: miR-146a-mediated suppression of the inflammatory response in human adipocytes publication-title: Sci. Rep. doi: 10.1038/srep38339 – volume: 395 start-page: 1695 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0045 article-title: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31042-4 – volume: 10 start-page: 2327 year: 1990 ident: 10.1016/j.mad.2020.111413_bib0075 article-title: Activation of interleukin-6 gene expression through the NF-kappa B transcription factor publication-title: Mol. Cell. Biol. – volume: 11 start-page: 566 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0205 article-title: Endothelial HSPA12B exerts protection against sepsis-induced severe cardiomyopathy via suppression of adhesion molecule expression by miR-126 publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.00566 – volume: 46 start-page: 846 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0150 article-title: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China publication-title: Intensive Care Med. doi: 10.1007/s00134-020-05991-x – volume: 395 start-page: 1054 issue: 10229 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0220 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 – volume: 30 start-page: 4407 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0070 article-title: CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) publication-title: Eur. Radiol. doi: 10.1007/s00330-020-06817-6 – volume: 111 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0080 article-title: Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2020.102452 – volume: 53 start-page: 33 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0020 article-title: Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2020.04.005 – volume: 9 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0105 article-title: Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells publication-title: J. Extracell. Vesicles doi: 10.1080/20013078.2020.1725285 – volume: 395 start-page: 1225 year: 2020 ident: 10.1016/j.mad.2020.111413_bib0140 article-title: COVID-19 and Italy: what next? publication-title: Lancet doi: 10.1016/S0140-6736(20)30627-9 – volume: 38 start-page: 1761 year: 2015 ident: 10.1016/j.mad.2020.111413_bib0065 article-title: miR-146a-5p antagonized AGEs- and P.g-LPS-Induced ABCA1 and ABCG1 dysregulation in macrophages via IRAK-1 downregulation publication-title: Inflammation doi: 10.1007/s10753-015-0153-x |
| SSID | ssj0001426 |
| Score | 2.5718384 |
| Snippet | •Tocilizumab (TCZ) is currently being tested in COVID‐19‐induced cytokine storm.•COVID-19 patients responding to TCZ have higher post-treatment levels of... Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 111413 |
| SubjectTerms | Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Biomarkers - blood Circulating MicroRNA - blood COVID-19 COVID-19 - blood COVID-19 - drug therapy COVID-19 - epidemiology Female Humans Inflammaging Inflammation - blood Inflammation - drug therapy Inflammation - epidemiology interleukin-6 Male microRNA MicroRNAs - blood Middle Aged Pandemics SARS-CoV-2 Tocilizumab |
| Title | Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients |
| URI | https://dx.doi.org/10.1016/j.mad.2020.111413 https://www.ncbi.nlm.nih.gov/pubmed/33307107 https://www.proquest.com/docview/2470035229 https://pubmed.ncbi.nlm.nih.gov/PMC7722494 |
| Volume | 193 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIhAX1G55LIXKSIgDkmni2NnmuNq22oJaJERRxcXyK2rQJqn2cYADZ342M46zsCB6QMrJsaNR5vN4xv5mTMhLo42R-ihn0smcCVM4psEMsjSFFwZQkOeYjXx-kU8vxdsrebVFJn0uDNIqo-3vbHqw1rHlMP7Nw5uqwhxfAZMDQjvAKU8KTPjF6nWA6Tfff9E8UhGuXMPODHv3J5uB41VrLBbKg-EQafavtelv3_NPCuVva9LpDnkQnUk67uTdJVu-GZC9cQOBdP2VvqKB3hn2zQfk3nk8RR-Qu5_b0LhHfhwHr3HhHQUormo6Qw7RgrYlBceQAvoAMHW4yIjWSOSZ07r6wMDuaarnnuqoXBiPG7q0z7OkTduweUe_9XTZwmOrWfVtVWsDX6WT95_Ojlla0FjWdfGQXJ6efJxMWbybgVlY45cs5bkBZ0Dz0hZpZnIntc-55sKVwlordekKJ31SOi3QhXG8wA1obUvpeaFt9ohsgyj-CaEjJ7JcCucTbkWRaAggXWKkORLaQPBZDEnSa0XZWLgc78-YqZ6h9kWBIhUqUnWKHJLX6yE3XdWO2zqLXtVqA3oKVpXbhr3oYaFgSuI5i258u1ooLkahzCwH0R93MFlLkWUZOnWjIRltAGjdAct9b75pqutQ9hviIIiVxdP_E3ef3OdIxwm7R8_I9nK-8s_Bn1qagzBhDsid8dm76cVPZcgfww |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTjBeEHRslE8jIR6QrCWOnTaPVcfUsrVIaEMTL5G_IoKadOrHA_wF_NmcHaeiIPaAlCfHjk65n89355_PAG-UVErIQUqFESnlKjNUohmkcYwvFKIgTd1p5OksHV_xD9fieg9G7VkYR6sMtr-x6d5ah5aT8DdPbsrSnfHlODkwtEOcsigb3IF9V52Kd2B_ODkfz7YGOeb-1jXXn7oB7eamp3lV0tULZd528Dj51_L0t_v5J4vyt2Xp7CE8CP4kGTYiP4I9W3fhcFhjLF19J2-JZ3j61HkX7k3DRnoX7n5Z-MZD-HnqHceVNQTRuKnI3NGIVmRREPQNCQIQMVP5u4xI5bg8S1KVnyiaPknk0hIZ9IvjXU6XtEctSb2o6bJh4FqyXuCjy3n5Y1NJhV8lo4-fJ6c0zkio7Lp6DFdn7y9HYxquZ6Aal_k1jVmq0B-QrNBZnKjUCGlTJhk3BddaC1mYzAgbFUZy58UYlrkctNSFsCyTOjmCDopinwDpG56kghsbMc2zSGIMaSIl1IBLhfFn1oOo1UquQ-1yd4XGPG9Jat9yVGTuFJk3iuzBu-2Qm6Zwx22deavqfAd9OS4stw173cIix1nptlpkbRebVc5431eaZSj6cQOTrRRJkji_rt-D_g6Ath1cxe_dN3X51Vf-xlAIw2X-9P_EfQUH48vpRX4xmZ0_g_vMsXN8Muk5dNbLjX2B7tVavQzT5xcujiJ0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+serum+levels+of+the+inflammaging+marker+miR-146a+are+associated+with+clinical+non-response+to+tocilizumab+in+COVID-19+patients&rft.jtitle=Mechanisms+of+ageing+and+development&rft.au=Sabbatinelli%2C+Jacopo&rft.au=Giuliani%2C+Angelica&rft.au=Matacchione%2C+Giulia&rft.au=Latini%2C+Silvia&rft.date=2021-01-01&rft.issn=1872-6216&rft.eissn=1872-6216&rft.volume=193&rft.spage=111413&rft_id=info:doi/10.1016%2Fj.mad.2020.111413&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0047-6374&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0047-6374&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0047-6374&client=summon |